{"title":"Evans syndrome in infants","authors":"Olivia Alejandra Flores-Montes , Martha Cecilia Escobar-Orduño , Mónica Lozano-Garcidueñas , Jaime Guadalupe Valle-Leal","doi":"10.1016/j.bmhime.2017.01.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Evans’ syndrome is characterized by the reduction of at least two blood cell lines in the absence of other diagnoses; it was previously described as the simultaneous or sequential development of autoimmune hemolytic anemia and immune thrombocytopenia with unknown etiology. Incidence of 37% and mortality rate of 10% have been reported for Evans’ syndrome.</p></div><div><h3>Clinical cases</h3><p>We report the clinical presentation and evolution of Evans’ syndrome in two infants who were initially diagnosed with immune thrombocytopenia. The clinical diagnosis was supported by complementary studies and hematological disorders were corroborated. Both cases received treatment with steroids and intravenous immunoglobulin.</p></div><div><h3>Conclusions</h3><p>Other cell line disorders must be looked for when approaching children with thrombocytopenia. In the present cases, we found autoimmune hemolytic anemia and monocytosis. Therefore, infectious and immunological studies must be included. The treatment of choice are steroids, and intravenous immunoglobulin should be considered if severe immune thrombocytopenia is associated, as observed in these cases.</p></div>","PeriodicalId":100195,"journal":{"name":"Boletín Médico Del Hospital Infantil de México (English Edition)","volume":"74 2","pages":"Pages 141-146"},"PeriodicalIF":0.0000,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bmhime.2017.01.001","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Boletín Médico Del Hospital Infantil de México (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2444340917000553","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background
Evans’ syndrome is characterized by the reduction of at least two blood cell lines in the absence of other diagnoses; it was previously described as the simultaneous or sequential development of autoimmune hemolytic anemia and immune thrombocytopenia with unknown etiology. Incidence of 37% and mortality rate of 10% have been reported for Evans’ syndrome.
Clinical cases
We report the clinical presentation and evolution of Evans’ syndrome in two infants who were initially diagnosed with immune thrombocytopenia. The clinical diagnosis was supported by complementary studies and hematological disorders were corroborated. Both cases received treatment with steroids and intravenous immunoglobulin.
Conclusions
Other cell line disorders must be looked for when approaching children with thrombocytopenia. In the present cases, we found autoimmune hemolytic anemia and monocytosis. Therefore, infectious and immunological studies must be included. The treatment of choice are steroids, and intravenous immunoglobulin should be considered if severe immune thrombocytopenia is associated, as observed in these cases.